# Chemoprevention Efficacy Study in Burkina Faso

> **NCT05478954** · PHASE4 · UNKNOWN · sponsor: **Malaria Consortium** · enrollment: 800 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Sulfadoxine pyrimethamine
- **DRUG:** Amodiaquine

## Key facts

- **NCT ID:** NCT05478954
- **Lead sponsor:** Malaria Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-15
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05478954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05478954, "Chemoprevention Efficacy Study in Burkina Faso". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05478954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*